Two primary approaches have been explored; one involving targeted drug delivery via folate-conjugated therapeutic compounds [9-12], and the other involving direct targeting and tumor cell death via humanized anti-FRA monoclonal antibodies [13-15]. The gene discussed is FOLR1; the disease is neoplasm.